Format

Send to

Choose Destination
Int J Infect Dis. 2019 Jan;78:15-21. doi: 10.1016/j.ijid.2018.09.001. Epub 2018 Sep 7.

First description of agonist and antagonist IP-10 in urine of patients with active TB.

Author information

1
Translational Research Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI)-IRCCS, Rome, Italy.
2
Institut Pasteur, Laboratoire Immunobiologie des Cellules Dendritiques, Département d'Immunologie, Paris, France; INSERM U1223, Institut Pasteur, Paris, France.
3
Respiratory Infectious Diseases Unit, "L. Spallanzani" National Institute for Infectious Diseases (INMI)-IRCCS, Rome, Italy.
4
Institute of Microbiology, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Roma - Università Cattolica del Sacro Cuore, Italy.
5
Department of Epidemiology and Preclinical Research, National Institutes for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, 00149, Italy.
6
Department of Epidemiology and Preclinical Research, National Institutes for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, 00149, Italy; Dipartimento di Scienze e Tecnologie Biologiche ed Ambientali, University of Salento, Lecce, 73100, Italy.
7
Center for Vaccine Research, Statens Serum Institut, Artillerivej 5, 2300 S, Denmark.
8
Translational Research Unit, Department of Epidemiology and Preclinical Research, "L. Spallanzani" National Institute for Infectious Diseases (INMI)-IRCCS, Rome, Italy. Electronic address: delia.goletti@inmi.it.

Abstract

OBJECTIVES:

Biomarkers for tuberculosis (TB) diagnosis and clinical management are needed to defeat TB. In chronic hepatitis, patients not responding to interferon/ribavirin treatment had high levels of an antagonist form of IP-10. Recently, antagonist IP-10 has been shown to be involved also in TB pathogenesis. Here, we investigated IP-10 agonist/antagonist forms as potential inflammatory biomarkers to support TB diagnosis and monitoring.

METHODS:

Total IP-10 and its agonist/antagonist forms were measured by SIMOA digital ELISA in urine obtained from patients with active TB at baseline and after treatment. Healthy donors (HD) and patients with pneumonia were enrolled as controls.

RESULTS:

Patients with active TB had significantly higher levels of total and agonist IP-10 at baseline compared to HD; conversely, no differences were observed between IP-10 levels in active TB vs pneumonia. Moreover, in active TB a decline of total urine IP-10 was observed at therapy completion; agonist/antagonist forms reflected this decline although their differences were not statistically significant.

CONCLUSIONS:

We showed for the first time that agonist/antagonist IP-10 forms are measurable in urine. IP-10 levels associate with TB and pneumonia disease, suggesting their association with acute inflammation. Further studies are needed to assess their role to monitor TB treatment efficacy.

KEYWORDS:

Biomarker; IP-10 antagonism; Treatment monitoring; Tuberculosis; Urine

PMID:
30201505
DOI:
10.1016/j.ijid.2018.09.001
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center